Ionis Pharmaceuticals, Inc. (IONS) 10-Year Financial Performance & Capital Metrics

IONS • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutIonis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.Show more

Revenue $705M -10.5%
EBITDA -$453M -36.8%
Net Income -$454M -23.9%
EPS (Diluted) -3.04 -18.8%
Gross Margin 98.41% -0.4%
EBITDA Margin -64.26% -52.8%
Operating Margin -67.37% -50.0%
Net Margin -64.37% -38.4%
ROE -93.1% -22.0%
ROIC -22.24% -30.2%
Debt/Equity 2.41 -35.9%
Interest Coverage -5.25 -21.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 90 (top 10%)

✗Weaknesses

✗High debt to equity ratio of 2.4x
✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Sales declining 8.9% over 5 years
✗Expensive at 19.6x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y12.66%

5Y-8.88%

3Y-4.53%

TTM20.41%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM28.56%

EPS CAGR

10Y-

5Y-

3Y-

TTM30.04%

ROCE

10Y Avg-5.79%

5Y Avg-11.91%

3Y Avg-16.95%

Latest-18.15%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	283.7M	372.78M	514.18M	599.67M	1.12B	729.26M	810.46M	587.37M	787.65M	705.14M
Revenue Growth %	0.32%	0.31%	0.38%	0.17%	0.87%	-0.35%	0.11%	-0.28%	0.34%	-0.1%
Cost of Goods Sold+	322.29M	0	0	1.82M	4.38M	11.95M	10.84M	14.12M	9.13M	11.21M
COGS % of Revenue	1.14%	-	-	0%	0%	0.02%	0.01%	0.02%	0.01%	0.02%
Gross Profit+	-38.59M	372.78M	514.18M	597.85M	1.12B	717.32M	799.61M	573.25M	778.51M	693.92M
Gross Margin %	-0.14%	1%	1%	1%	1%	0.98%	0.99%	0.98%	0.99%	0.98%
Gross Profit Growth %	-0.4%	10.66%	0.38%	0.16%	0.87%	-0.36%	0.11%	-0.28%	0.36%	-0.11%
Operating Expenses+	37.17M	392.94M	483.13M	659.23M	752.33M	889.4M	829.8M	983.44M	1.13B	1.17B
OpEx % of Revenue	0.13%	1.05%	0.94%	1.1%	0.67%	1.22%	1.02%	1.67%	1.44%	1.66%
Selling, General & Admin	37.17M	48.62M	108.49M	244.62M	286.64M	332.2M	170.9M	150.29M	232.6M	267.5M
SG&A % of Revenue	0.13%	0.13%	0.21%	0.41%	0.26%	0.46%	0.21%	0.26%	0.3%	0.38%
Research & Development	322.29M	344.32M	374.64M	414.6M	466M	535M	643M	833M	899.63M	901.53M
R&D % of Revenue	1.14%	0.92%	0.73%	0.69%	0.42%	0.73%	0.79%	1.42%	1.14%	1.28%
Other Operating Expenses	-322.29M	0	0	0	0	22.12M	15.45M	0	19K	-26K
Operating Income+	-75.76M	-20.16M	31.05M	-61.37M	365.88M	-172.08M	-30.19M	-410.19M	-353.73M	-475.08M
Operating Margin %	-0.27%	-0.05%	0.06%	-0.1%	0.33%	-0.24%	-0.04%	-0.7%	-0.45%	-0.67%
Operating Income Growth %	-0.59%	0.73%	2.54%	-2.98%	6.96%	-1.47%	0.82%	-12.59%	0.14%	-0.34%
EBITDA+	-65.52M	-11.13M	39.4M	-48.84M	381.88M	-154.92M	-10.63M	-388.09M	-331.23M	-453.09M
EBITDA Margin %	-0.23%	-0.03%	0.08%	-0.08%	0.34%	-0.21%	-0.01%	-0.66%	-0.42%	-0.64%
EBITDA Growth %	-0.71%	0.83%	4.54%	-2.24%	8.82%	-1.41%	0.93%	-35.52%	0.15%	-0.37%
D&A (Non-Cash Add-back)	10.24M	9.03M	8.35M	12.53M	15.99M	17.16M	19.56M	22.11M	22.5M	21.99M
EBIT	-51.17M	-18.67M	27.99M	-31.37M	351.21M	-128.35M	-24.75M	-249.86M	-258.37M	-375.71M
Net Interest Income+	-32.43M	-33.38M	-36.57M	-14.6M	3.44M	21.05M	695K	17.21M	7.58M	16.57M
Interest Income	4.3M	5.42M	8.18M	30.19M	52.2M	30.56M	10.04M	25.33M	89.04M	107.02M
Interest Expense	36.73M	38.8M	44.75M	44.79M	48.77M	9.51M	9.35M	8.12M	81.46M	90.45M
Other Income/Expense	-12.14M	-37.31M	-47.81M	-14.78M	-27.12M	37.53M	1.04M	152.21M	19.77M	15.01M
Pretax Income+	-87.91M	-57.47M	-16.76M	-76.16M	338.77M	-134.55M	-29.15M	-257.99M	-333.96M	-460.07M
Pretax Margin %	-0.31%	-0.15%	-0.03%	-0.13%	0.3%	-0.18%	-0.04%	-0.44%	-0.42%	-0.65%
Income Tax+	372K	2.93M	-5.98M	-291.14M	51.51M	345.19M	-551K	11.74M	32.32M	-6.17M
Effective Tax Rate %	1%	1.05%	-0.02%	-3.59%	0.82%	3.3%	0.98%	1.05%	1.1%	0.99%
Net Income+	-88.28M	-60.4M	346K	273.74M	278.14M	-444.26M	-28.6M	-269.72M	-366.29M	-453.9M
Net Margin %	-0.31%	-0.16%	0%	0.46%	0.25%	-0.61%	-0.04%	-0.46%	-0.47%	-0.64%
Net Income Growth %	-1.26%	0.32%	1.01%	790.16%	0.02%	-2.6%	0.94%	-8.43%	-0.36%	-0.24%
Net Income (Continuing)	-88.28M	-60.4M	-10.78M	214.99M	287.26M	-479.74M	-28.6M	-269.72M	-366.29M	-453.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	84.27M	139.08M	213.45M	0	0	0	0	0
EPS (Diluted)+	-0.74	-0.72	-0.05	2.04	2.06	-3.18	-0.20	-1.90	-2.56	-3.04
EPS Growth %	-1.24%	0.03%	0.93%	44.13%	0.01%	-2.54%	0.94%	-8.5%	-0.35%	-0.19%
EPS (Basic)	-0.74	-0.72	-0.05	2.07	2.10	-3.18	-0.20	-1.90	-2.56	-3.04
Diluted Shares Outstanding	119.72M	120.93M	126.1M	134.06M	142.87M	139.61M	141.02M	141.85M	143.19M	149.51M
Basic Shares Outstanding	119.29M	120.8M	124.02M	132.32M	140M	139.61M	141.02M	141.85M	143M	149.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	837M	797.93M	1.17B	2.21B	2.72B	2.13B	2.35B	2.2B	2.64B	2.62B
Cash & Short-Term Investments	803.98M	665.22M	1.02B	2.08B	2.5B	1.89B	2.13B	2B	2.33B	2.3B
Cash Only	128.8M	84.69M	129.63M	278.82M	683.29M	397.66M	869.19M	276.47M	399.27M	242.08M
Short-Term Investments	24.79M	2.41M	893.09M	1.81B	1.82B	1.49B	1.26B	1.72B	1.93B	2.06B
Accounts Receivable	11.36M	108.04M	62.95M	12.76M	63.03M	76.2M	61.9M	25.54M	97.78M	92.19M
Days Sales Outstanding	14.61	105.79	44.69	7.77	20.49	38.14	27.88	15.87	45.31	47.72
Inventory	6.9M	7.49M	9.98M	8.58M	18.18M	21.96M	24.81M	22.03M	7.44M	12.51M
Days Inventory Outstanding	7.81	-	-	1.72K	1.51K	671.07	835.1	569.71	297.38	407.21
Other Current Assets	14.77M	17.18M	73.08M	102.47M	139.84M	140.16M	125.17M	157.72M	205.43M	217.93M
Total Non-Current Assets+	110.9M	114.53M	154.04M	459.9M	512.51M	259.05M	266.64M	331.18M	348.22M	383.38M
Property, Plant & Equipment	90.23M	92.84M	121.91M	132.16M	153.65M	181.08M	196.04M	255.84M	242.94M	256.11M
Fixed Asset Turnover	3.14x	4.02x	4.22x	4.54x	7.31x	4.03x	4.13x	2.30x	3.24x	2.75x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	19.32M	20.36M	22M	24.03M	25.67M	27.94M	29M	0	0	0
Long-Term Investments	0	0	0	0	0	15.06M	32.32M	40.37M	42.99M	41.02M
Other Non-Current Assets	1.35M	1.32M	10.13M	12.91M	27.63M	34.97M	9.27M	34.97M	62.29M	86.25M
Total Assets+	947.9M	912.47M	1.32B	2.67B	3.23B	2.39B	2.61B	2.53B	2.99B	3B
Asset Turnover	0.30x	0.41x	0.39x	0.22x	0.35x	0.31x	0.31x	0.23x	0.26x	0.23x
Asset Growth %	-0.01%	-0.04%	0.45%	1.02%	0.21%	-0.26%	0.09%	-0.03%	0.18%	0%
Total Current Liabilities+	148.88M	133.78M	243.61M	280.29M	273M	598.9M	240.55M	311.56M	448.09M	309.32M
Accounts Payable	28.36M	21.12M	24.89M	28.66M	16.07M	17.2M	11.9M	17.92M	26.03M	42.96M
Days Payables Outstanding	32.11	-	-	5.75K	1.34K	525.46	400.75	463.39	1.04K	1.4K
Short-Term Debt	9.03M	1.19M	1.62M	13.75M	2.03M	308.81M	3.53M	7.54M	53.16M	9.28M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	16.07M	24.19M	25.15M	29.27M	37.36M	73.03M	38.81M	49.18M	67.73M	69.61M
Current Ratio	5.62x	5.96x	4.80x	7.88x	9.97x	3.56x	9.75x	7.07x	5.90x	8.47x
Quick Ratio	5.58x	5.91x	4.76x	7.85x	9.90x	3.52x	9.65x	7.00x	5.88x	8.43x
Cash Conversion Cycle	-9.69	-	-	-4.02K	196.42	183.75	462.23	122.19	-697.48	-943.36
Total Non-Current Liabilities+	598.23M	679.12M	713.88M	1.2B	1.28B	1.05B	1.6B	1.65B	2.16B	2.11B
Long-Term Debt	389.37M	500.51M	592.88M	628.06M	769.96M	600.12M	1.23B	1.18B	1.23B	1.25B
Capital Lease Obligations	72.22M	72.36M	0	0	0	0	19.43M	178.94M	170.88M	161.81M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.34M	15.05M	12.97M	4.91M	15.54M	23.41M	0	0	513.74M	542.21M
Total Liabilities	747.11M	812.9M	957.49M	1.48B	1.55B	1.65B	1.84B	1.96B	2.6B	2.42B
Total Debt+	470.62M	574.05M	594.5M	641.81M	771.98M	908.93M	1.25B	1.37B	1.45B	1.42B
Net Debt	341.82M	489.37M	464.87M	362.99M	88.7M	511.26M	381.86M	1.09B	1.05B	1.17B
Debt / Equity	2.34x	5.77x	1.63x	0.54x	0.46x	1.22x	1.62x	2.39x	3.76x	2.41x
Debt / EBITDA	-	-	15.09x	-	2.02x	-	-	-	-	-
Net Debt / EBITDA	-	-	11.80x	-	0.23x	-	-	-	-	-
Interest Coverage	-2.06x	-0.52x	0.69x	-1.37x	7.50x	-18.09x	-3.23x	-50.50x	-4.34x	-5.25x
Total Equity+	200.79M	99.56M	365.28M	1.19B	1.68B	743.28M	771.74M	572.89M	386.69M	588.35M
Equity Growth %	-0.22%	-0.5%	2.67%	2.25%	0.42%	-0.56%	0.04%	-0.26%	-0.33%	0.52%
Book Value per Share	1.68	0.82	2.90	8.86	11.79	5.32	5.47	4.04	2.70	3.94
Total Shareholders' Equity	200.79M	99.56M	281.01M	1.05B	1.47B	743.28M	771.74M	572.89M	386.69M	588.35M
Common Stock	120K	122K	125K	138K	140K	140K	141K	142K	144K	158K
Retained Earnings	-1.09B	-1.18B	-1.19B	-967.29M	-707.53M	-1.13B	-1.16B	-1.43B	-1.8B	-2.25B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-13.56M	-30.36M	-31.76M	-32.02M	-25.29M	-21.07M	-32.67M	-57.48M	-32.65M	-30.81M
Minority Interest	0	0	84.27M	139.08M	213.45M	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	21.13M	-112.11M	174.15M	602.89M	345.72M	35.89M	30.8M	-274.37M	-307.51M	-500.95M
Operating CF Margin %	0.07%	-0.3%	0.34%	1.01%	0.31%	0.05%	0.04%	-0.47%	-0.39%	-0.71%
Operating CF Growth %	2.36%	-6.31%	2.55%	2.46%	-0.43%	-0.9%	-0.14%	-9.91%	-0.12%	-0.63%
Net Income	-88.28M	-86.56M	-17.3M	214.99M	303.26M	-486.77M	-28.6M	-269.72M	-366.29M	-453.9M
Depreciation & Amortization	10.24M	9.03M	8.35M	12.53M	15.99M	17.16M	19.56M	22.11M	22.5M	19.65M
Stock-Based Compensation	59.31M	72.11M	85.97M	131.31M	146.57M	230.12M	120.68M	100.26M	105.81M	130.2M
Deferred Taxes	-12.47M	10.74M	14.07M	-290.52M	-7.1M	313.27M	25.31M	0	0	0
Other Non-Cash Items	31.75M	34.1M	39.5M	35.17M	55.69M	35.66M	7.67M	-134.59M	7.73M	12.49M
Working Capital Changes	20.57M	-151.53M	43.56M	499.41M	-168.71M	-73.56M	-113.82M	7.57M	-77.26M	-209.39M
Change in Receivables	-14.12M	-89.36M	15.72M	514K	-44.18M	-22M	5.05M	36.36M	-72.06M	5.59M
Change in Inventory	-609K	-590K	-2.49M	1.4M	-5.41M	-1.26M	-2.84M	2.77M	-6.39M	-5.07M
Change in Payables	9.21M	-10.68M	1.78M	-655K	-16.34M	-2.75M	-6M	1.09M	8.12M	15.99M
Cash from Investing+	-60.05M	56.6M	-358.29M	-929.56M	-41.27M	274.48M	194.91M	-262.64M	-214.13M	-134.03M
Capital Expenditures	-11.75M	-11.53M	-37.86M	-17.65M	-36.28M	-41.05M	-17.9M	-20.1M	-23.8M	-45.28M
CapEx % of Revenue	0.04%	0.03%	0.07%	0.03%	0.03%	0.06%	0.02%	0.03%	0.03%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-52.36M	63.71M	-323.53M	-4.04M	-5.38M	-5.93M	-5.95M	0	-4.21M	-5.06M
Cash from Financing+	24.73M	11.39M	229.09M	475.87M	100.02M	-596.61M	245.93M	-55.3M	644.08M	478.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	396K	1.04M	-2.04M	0	-82.24M	-492.65M	-79.2M	-10.98M	507.74M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	9.38M	-123.63M	136.29M	585.24M	309.44M	-5.16M	12.9M	-294.47M	-335.52M	-546.23M
FCF Margin %	0.03%	-0.33%	0.27%	0.98%	0.28%	-0.01%	0.02%	-0.5%	-0.43%	-0.77%
FCF Growth %	2.95%	-14.18%	2.1%	3.29%	-0.47%	-1.02%	3.5%	-23.83%	-0.14%	-0.63%
FCF per Share	0.08	-1.02	1.08	4.37	2.17	-0.04	0.09	-2.08	-2.34	-3.65
FCF Conversion (FCF/Net Income)	-0.24x	1.86x	503.32x	2.20x	1.24x	-0.08x	-1.08x	1.02x	0.84x	1.10x
Interest Paid	0	0	0	0	9.87M	6.25M	4.78M	2.9M	6.51M	0
Taxes Paid	0	0	0	0	9.04M	25.86M	38K	5.01M	48.33M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-38.5%	-40.22%	0.15%	35.27%	19.37%	-36.6%	-3.78%	-40.12%	-76.34%	-93.1%
Return on Invested Capital (ROIC)	-10.26%	-2.67%	3.28%	-3.87%	16.51%	-8.53%	-1.88%	-21.82%	-17.08%	-22.24%
Gross Margin	-13.6%	100%	100%	99.7%	99.61%	98.36%	98.66%	97.6%	98.84%	98.41%
Net Margin	-31.12%	-16.2%	0.07%	45.65%	24.78%	-60.92%	-3.53%	-45.92%	-46.5%	-64.37%
Debt / Equity	2.34x	5.77x	1.63x	0.54x	0.46x	1.22x	1.62x	2.39x	3.76x	2.41x
Interest Coverage	-2.06x	-0.52x	0.69x	-1.37x	7.50x	-18.09x	-3.23x	-50.50x	-4.34x	-5.25x
FCF Conversion	-0.24x	1.86x	503.32x	2.20x	1.24x	-0.08x	-1.08x	1.02x	0.84x	1.10x
Revenue Growth	32.47%	31.4%	37.93%	16.63%	87.2%	-35.04%	11.13%	-27.53%	34.1%	-10.48%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Research and Development Revenue	-	-	-	-	-	-	-	284.01M	479.06M	412.06M
Research and Development Revenue Growth	-	-	-	-	-	-	-	-	68.68%	-13.98%
Collaborative Agreement Revenue	-	-	-	-	-	-	-	207.22M	352.66M	332.65M
Collaborative Agreement Revenue Growth	-	-	-	-	-	-	-	-	70.18%	-5.67%
Commercial	-	-	-	254.92M	352.45M	364.7M	342.39M	303.36M	308.59M	293.08M
Commercial Growth	-	-	-	-	38.26%	3.48%	-6.12%	-11.40%	1.73%	-5.03%
SPINRAZA Royalties	-	-	-	237.93M	292.99M	-	-	-	240.38M	216.09M
SPINRAZA Royalties Growth	-	-	-	-	23.14%	-	-	-	-	-10.10%
Other Commercial	-	-	-	-	-	-	-	-	68.21M	56.78M
Other Commercial Growth	-	-	-	-	-	-	-	-	-	-16.76%
Product	-	-	-	2.24M	42.25M	70M	-	30.05M	34.91M	34.19M
Product Growth	-	-	-	-	1788.82%	65.67%	-	-	16.18%	-2.07%
Other	-	-	-	-	-	-	-	-	-	22.59M
Other Growth	-	-	-	-	-	-	-	-	-	-
Licensing and Other Royalties	-	-	-	14.76M	17.2M	8.12M	19.12M	30.99M	33.3M	-
Licensing and Other Royalties Growth	-	-	-	-	16.60%	-52.82%	135.54%	62.11%	7.44%	-
Spinraza Royalties	-	-	-	-	-	286.58M	267.78M	242.31M	-	-
Spinraza Royalties Growth	-	-	-	-	-	-	-6.56%	-9.51%	-	-
Eplontersen Joint Development Revenue	-	-	-	-	-	-	-	76.79M	-	-
Eplontersen Joint Development Revenue Growth	-	-	-	-	-	-	-	-	-	-
Research and Development Revenue Under Collaborative Agreements	-	-	-	344.75M	770.15M	364.56M	468.06M	-	-	-
Research and Development Revenue Under Collaborative Agreements Growth	-	-	-	-	123.39%	-52.66%	28.39%	-	-	-
TEGSEDI and WAYLIVRA	-	-	-	-	-	-	55.5M	-	-	-
TEGSEDI and WAYLIVRA Growth	-	-	-	-	-	-	-	-	-	-
Akcea Therapeutics	-	-	-	-	-	-	-	-	-	-
Akcea Therapeutics Growth	-	-	-	-	-	-	-	-	-	-
Nusinersen	40M	-	-	-	-	-	-	-	-	-
Nusinersen Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Ionis Pharmaceuticals, Inc. (IONS) reported $967.0M in revenue for fiscal year 2024. This represents a 876% increase from $99.1M in 2011.

Ionis Pharmaceuticals, Inc. (IONS) saw revenue decline by 10.5% over the past year.

Ionis Pharmaceuticals, Inc. (IONS) reported a net loss of $256.3M for fiscal year 2024.

Dividend & Returns

Ionis Pharmaceuticals, Inc. (IONS) has a return on equity (ROE) of -93.1%. Negative ROE indicates the company is unprofitable.

Ionis Pharmaceuticals, Inc. (IONS) had negative free cash flow of $302.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Ionis Pharmaceuticals, Inc. (IONS) 10-Year Financial Performance & Capital Metrics

IONS • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $705M -10.5%
EBITDA -$453M -36.8%
Net Income -$454M -23.9%
EPS (Diluted) -3.04 -18.8%
Gross Margin 98.41% -0.4%
EBITDA Margin -64.26% -52.8%
Operating Margin -67.37% -50.0%
Net Margin -64.37% -38.4%
ROE -93.1% -22.0%
ROIC -22.24% -30.2%
Debt/Equity 2.41 -35.9%
Interest Coverage -5.25 -21.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 90 (top 10%)

✗Weaknesses

✗High debt to equity ratio of 2.4x
✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Sales declining 8.9% over 5 years
✗Expensive at 19.6x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y12.66%

5Y-8.88%

3Y-4.53%

TTM20.41%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM28.56%

EPS CAGR

10Y-

5Y-

3Y-

TTM30.04%

ROCE

10Y Avg-5.79%

5Y Avg-11.91%

3Y Avg-16.95%

Latest-18.15%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	283.7M	372.78M	514.18M	599.67M	1.12B	729.26M	810.46M	587.37M	787.65M	705.14M
Revenue Growth %	0.32%	0.31%	0.38%	0.17%	0.87%	-0.35%	0.11%	-0.28%	0.34%	-0.1%
Cost of Goods Sold+	322.29M	0	0	1.82M	4.38M	11.95M	10.84M	14.12M	9.13M	11.21M
COGS % of Revenue	1.14%	-	-	0%	0%	0.02%	0.01%	0.02%	0.01%	0.02%
Gross Profit+	-38.59M	372.78M	514.18M	597.85M	1.12B	717.32M	799.61M	573.25M	778.51M	693.92M
Gross Margin %	-0.14%	1%	1%	1%	1%	0.98%	0.99%	0.98%	0.99%	0.98%
Gross Profit Growth %	-0.4%	10.66%	0.38%	0.16%	0.87%	-0.36%	0.11%	-0.28%	0.36%	-0.11%
Operating Expenses+	37.17M	392.94M	483.13M	659.23M	752.33M	889.4M	829.8M	983.44M	1.13B	1.17B
OpEx % of Revenue	0.13%	1.05%	0.94%	1.1%	0.67%	1.22%	1.02%	1.67%	1.44%	1.66%
Selling, General & Admin	37.17M	48.62M	108.49M	244.62M	286.64M	332.2M	170.9M	150.29M	232.6M	267.5M
SG&A % of Revenue	0.13%	0.13%	0.21%	0.41%	0.26%	0.46%	0.21%	0.26%	0.3%	0.38%
Research & Development	322.29M	344.32M	374.64M	414.6M	466M	535M	643M	833M	899.63M	901.53M
R&D % of Revenue	1.14%	0.92%	0.73%	0.69%	0.42%	0.73%	0.79%	1.42%	1.14%	1.28%
Other Operating Expenses	-322.29M	0	0	0	0	22.12M	15.45M	0	19K	-26K
Operating Income+	-75.76M	-20.16M	31.05M	-61.37M	365.88M	-172.08M	-30.19M	-410.19M	-353.73M	-475.08M
Operating Margin %	-0.27%	-0.05%	0.06%	-0.1%	0.33%	-0.24%	-0.04%	-0.7%	-0.45%	-0.67%
Operating Income Growth %	-0.59%	0.73%	2.54%	-2.98%	6.96%	-1.47%	0.82%	-12.59%	0.14%	-0.34%
EBITDA+	-65.52M	-11.13M	39.4M	-48.84M	381.88M	-154.92M	-10.63M	-388.09M	-331.23M	-453.09M
EBITDA Margin %	-0.23%	-0.03%	0.08%	-0.08%	0.34%	-0.21%	-0.01%	-0.66%	-0.42%	-0.64%
EBITDA Growth %	-0.71%	0.83%	4.54%	-2.24%	8.82%	-1.41%	0.93%	-35.52%	0.15%	-0.37%
D&A (Non-Cash Add-back)	10.24M	9.03M	8.35M	12.53M	15.99M	17.16M	19.56M	22.11M	22.5M	21.99M
EBIT	-51.17M	-18.67M	27.99M	-31.37M	351.21M	-128.35M	-24.75M	-249.86M	-258.37M	-375.71M
Net Interest Income+	-32.43M	-33.38M	-36.57M	-14.6M	3.44M	21.05M	695K	17.21M	7.58M	16.57M
Interest Income	4.3M	5.42M	8.18M	30.19M	52.2M	30.56M	10.04M	25.33M	89.04M	107.02M
Interest Expense	36.73M	38.8M	44.75M	44.79M	48.77M	9.51M	9.35M	8.12M	81.46M	90.45M
Other Income/Expense	-12.14M	-37.31M	-47.81M	-14.78M	-27.12M	37.53M	1.04M	152.21M	19.77M	15.01M
Pretax Income+	-87.91M	-57.47M	-16.76M	-76.16M	338.77M	-134.55M	-29.15M	-257.99M	-333.96M	-460.07M
Pretax Margin %	-0.31%	-0.15%	-0.03%	-0.13%	0.3%	-0.18%	-0.04%	-0.44%	-0.42%	-0.65%
Income Tax+	372K	2.93M	-5.98M	-291.14M	51.51M	345.19M	-551K	11.74M	32.32M	-6.17M
Effective Tax Rate %	1%	1.05%	-0.02%	-3.59%	0.82%	3.3%	0.98%	1.05%	1.1%	0.99%
Net Income+	-88.28M	-60.4M	346K	273.74M	278.14M	-444.26M	-28.6M	-269.72M	-366.29M	-453.9M
Net Margin %	-0.31%	-0.16%	0%	0.46%	0.25%	-0.61%	-0.04%	-0.46%	-0.47%	-0.64%
Net Income Growth %	-1.26%	0.32%	1.01%	790.16%	0.02%	-2.6%	0.94%	-8.43%	-0.36%	-0.24%
Net Income (Continuing)	-88.28M	-60.4M	-10.78M	214.99M	287.26M	-479.74M	-28.6M	-269.72M	-366.29M	-453.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	84.27M	139.08M	213.45M	0	0	0	0	0
EPS (Diluted)+	-0.74	-0.72	-0.05	2.04	2.06	-3.18	-0.20	-1.90	-2.56	-3.04
EPS Growth %	-1.24%	0.03%	0.93%	44.13%	0.01%	-2.54%	0.94%	-8.5%	-0.35%	-0.19%
EPS (Basic)	-0.74	-0.72	-0.05	2.07	2.10	-3.18	-0.20	-1.90	-2.56	-3.04
Diluted Shares Outstanding	119.72M	120.93M	126.1M	134.06M	142.87M	139.61M	141.02M	141.85M	143.19M	149.51M
Basic Shares Outstanding	119.29M	120.8M	124.02M	132.32M	140M	139.61M	141.02M	141.85M	143M	149.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	837M	797.93M	1.17B	2.21B	2.72B	2.13B	2.35B	2.2B	2.64B	2.62B
Cash & Short-Term Investments	803.98M	665.22M	1.02B	2.08B	2.5B	1.89B	2.13B	2B	2.33B	2.3B
Cash Only	128.8M	84.69M	129.63M	278.82M	683.29M	397.66M	869.19M	276.47M	399.27M	242.08M
Short-Term Investments	24.79M	2.41M	893.09M	1.81B	1.82B	1.49B	1.26B	1.72B	1.93B	2.06B
Accounts Receivable	11.36M	108.04M	62.95M	12.76M	63.03M	76.2M	61.9M	25.54M	97.78M	92.19M
Days Sales Outstanding	14.61	105.79	44.69	7.77	20.49	38.14	27.88	15.87	45.31	47.72
Inventory	6.9M	7.49M	9.98M	8.58M	18.18M	21.96M	24.81M	22.03M	7.44M	12.51M
Days Inventory Outstanding	7.81	-	-	1.72K	1.51K	671.07	835.1	569.71	297.38	407.21
Other Current Assets	14.77M	17.18M	73.08M	102.47M	139.84M	140.16M	125.17M	157.72M	205.43M	217.93M
Total Non-Current Assets+	110.9M	114.53M	154.04M	459.9M	512.51M	259.05M	266.64M	331.18M	348.22M	383.38M
Property, Plant & Equipment	90.23M	92.84M	121.91M	132.16M	153.65M	181.08M	196.04M	255.84M	242.94M	256.11M
Fixed Asset Turnover	3.14x	4.02x	4.22x	4.54x	7.31x	4.03x	4.13x	2.30x	3.24x	2.75x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	19.32M	20.36M	22M	24.03M	25.67M	27.94M	29M	0	0	0
Long-Term Investments	0	0	0	0	0	15.06M	32.32M	40.37M	42.99M	41.02M
Other Non-Current Assets	1.35M	1.32M	10.13M	12.91M	27.63M	34.97M	9.27M	34.97M	62.29M	86.25M
Total Assets+	947.9M	912.47M	1.32B	2.67B	3.23B	2.39B	2.61B	2.53B	2.99B	3B
Asset Turnover	0.30x	0.41x	0.39x	0.22x	0.35x	0.31x	0.31x	0.23x	0.26x	0.23x
Asset Growth %	-0.01%	-0.04%	0.45%	1.02%	0.21%	-0.26%	0.09%	-0.03%	0.18%	0%
Total Current Liabilities+	148.88M	133.78M	243.61M	280.29M	273M	598.9M	240.55M	311.56M	448.09M	309.32M
Accounts Payable	28.36M	21.12M	24.89M	28.66M	16.07M	17.2M	11.9M	17.92M	26.03M	42.96M
Days Payables Outstanding	32.11	-	-	5.75K	1.34K	525.46	400.75	463.39	1.04K	1.4K
Short-Term Debt	9.03M	1.19M	1.62M	13.75M	2.03M	308.81M	3.53M	7.54M	53.16M	9.28M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	16.07M	24.19M	25.15M	29.27M	37.36M	73.03M	38.81M	49.18M	67.73M	69.61M
Current Ratio	5.62x	5.96x	4.80x	7.88x	9.97x	3.56x	9.75x	7.07x	5.90x	8.47x
Quick Ratio	5.58x	5.91x	4.76x	7.85x	9.90x	3.52x	9.65x	7.00x	5.88x	8.43x
Cash Conversion Cycle	-9.69	-	-	-4.02K	196.42	183.75	462.23	122.19	-697.48	-943.36
Total Non-Current Liabilities+	598.23M	679.12M	713.88M	1.2B	1.28B	1.05B	1.6B	1.65B	2.16B	2.11B
Long-Term Debt	389.37M	500.51M	592.88M	628.06M	769.96M	600.12M	1.23B	1.18B	1.23B	1.25B
Capital Lease Obligations	72.22M	72.36M	0	0	0	0	19.43M	178.94M	170.88M	161.81M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.34M	15.05M	12.97M	4.91M	15.54M	23.41M	0	0	513.74M	542.21M
Total Liabilities	747.11M	812.9M	957.49M	1.48B	1.55B	1.65B	1.84B	1.96B	2.6B	2.42B
Total Debt+	470.62M	574.05M	594.5M	641.81M	771.98M	908.93M	1.25B	1.37B	1.45B	1.42B
Net Debt	341.82M	489.37M	464.87M	362.99M	88.7M	511.26M	381.86M	1.09B	1.05B	1.17B
Debt / Equity	2.34x	5.77x	1.63x	0.54x	0.46x	1.22x	1.62x	2.39x	3.76x	2.41x
Debt / EBITDA	-	-	15.09x	-	2.02x	-	-	-	-	-
Net Debt / EBITDA	-	-	11.80x	-	0.23x	-	-	-	-	-
Interest Coverage	-2.06x	-0.52x	0.69x	-1.37x	7.50x	-18.09x	-3.23x	-50.50x	-4.34x	-5.25x
Total Equity+	200.79M	99.56M	365.28M	1.19B	1.68B	743.28M	771.74M	572.89M	386.69M	588.35M
Equity Growth %	-0.22%	-0.5%	2.67%	2.25%	0.42%	-0.56%	0.04%	-0.26%	-0.33%	0.52%
Book Value per Share	1.68	0.82	2.90	8.86	11.79	5.32	5.47	4.04	2.70	3.94
Total Shareholders' Equity	200.79M	99.56M	281.01M	1.05B	1.47B	743.28M	771.74M	572.89M	386.69M	588.35M
Common Stock	120K	122K	125K	138K	140K	140K	141K	142K	144K	158K
Retained Earnings	-1.09B	-1.18B	-1.19B	-967.29M	-707.53M	-1.13B	-1.16B	-1.43B	-1.8B	-2.25B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-13.56M	-30.36M	-31.76M	-32.02M	-25.29M	-21.07M	-32.67M	-57.48M	-32.65M	-30.81M
Minority Interest	0	0	84.27M	139.08M	213.45M	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	21.13M	-112.11M	174.15M	602.89M	345.72M	35.89M	30.8M	-274.37M	-307.51M	-500.95M
Operating CF Margin %	0.07%	-0.3%	0.34%	1.01%	0.31%	0.05%	0.04%	-0.47%	-0.39%	-0.71%
Operating CF Growth %	2.36%	-6.31%	2.55%	2.46%	-0.43%	-0.9%	-0.14%	-9.91%	-0.12%	-0.63%
Net Income	-88.28M	-86.56M	-17.3M	214.99M	303.26M	-486.77M	-28.6M	-269.72M	-366.29M	-453.9M
Depreciation & Amortization	10.24M	9.03M	8.35M	12.53M	15.99M	17.16M	19.56M	22.11M	22.5M	19.65M
Stock-Based Compensation	59.31M	72.11M	85.97M	131.31M	146.57M	230.12M	120.68M	100.26M	105.81M	130.2M
Deferred Taxes	-12.47M	10.74M	14.07M	-290.52M	-7.1M	313.27M	25.31M	0	0	0
Other Non-Cash Items	31.75M	34.1M	39.5M	35.17M	55.69M	35.66M	7.67M	-134.59M	7.73M	12.49M
Working Capital Changes	20.57M	-151.53M	43.56M	499.41M	-168.71M	-73.56M	-113.82M	7.57M	-77.26M	-209.39M
Change in Receivables	-14.12M	-89.36M	15.72M	514K	-44.18M	-22M	5.05M	36.36M	-72.06M	5.59M
Change in Inventory	-609K	-590K	-2.49M	1.4M	-5.41M	-1.26M	-2.84M	2.77M	-6.39M	-5.07M
Change in Payables	9.21M	-10.68M	1.78M	-655K	-16.34M	-2.75M	-6M	1.09M	8.12M	15.99M
Cash from Investing+	-60.05M	56.6M	-358.29M	-929.56M	-41.27M	274.48M	194.91M	-262.64M	-214.13M	-134.03M
Capital Expenditures	-11.75M	-11.53M	-37.86M	-17.65M	-36.28M	-41.05M	-17.9M	-20.1M	-23.8M	-45.28M
CapEx % of Revenue	0.04%	0.03%	0.07%	0.03%	0.03%	0.06%	0.02%	0.03%	0.03%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-52.36M	63.71M	-323.53M	-4.04M	-5.38M	-5.93M	-5.95M	0	-4.21M	-5.06M
Cash from Financing+	24.73M	11.39M	229.09M	475.87M	100.02M	-596.61M	245.93M	-55.3M	644.08M	478.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	396K	1.04M	-2.04M	0	-82.24M	-492.65M	-79.2M	-10.98M	507.74M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	9.38M	-123.63M	136.29M	585.24M	309.44M	-5.16M	12.9M	-294.47M	-335.52M	-546.23M
FCF Margin %	0.03%	-0.33%	0.27%	0.98%	0.28%	-0.01%	0.02%	-0.5%	-0.43%	-0.77%
FCF Growth %	2.95%	-14.18%	2.1%	3.29%	-0.47%	-1.02%	3.5%	-23.83%	-0.14%	-0.63%
FCF per Share	0.08	-1.02	1.08	4.37	2.17	-0.04	0.09	-2.08	-2.34	-3.65
FCF Conversion (FCF/Net Income)	-0.24x	1.86x	503.32x	2.20x	1.24x	-0.08x	-1.08x	1.02x	0.84x	1.10x
Interest Paid	0	0	0	0	9.87M	6.25M	4.78M	2.9M	6.51M	0
Taxes Paid	0	0	0	0	9.04M	25.86M	38K	5.01M	48.33M	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-38.5%	-40.22%	0.15%	35.27%	19.37%	-36.6%	-3.78%	-40.12%	-76.34%	-93.1%
Return on Invested Capital (ROIC)	-10.26%	-2.67%	3.28%	-3.87%	16.51%	-8.53%	-1.88%	-21.82%	-17.08%	-22.24%
Gross Margin	-13.6%	100%	100%	99.7%	99.61%	98.36%	98.66%	97.6%	98.84%	98.41%
Net Margin	-31.12%	-16.2%	0.07%	45.65%	24.78%	-60.92%	-3.53%	-45.92%	-46.5%	-64.37%
Debt / Equity	2.34x	5.77x	1.63x	0.54x	0.46x	1.22x	1.62x	2.39x	3.76x	2.41x
Interest Coverage	-2.06x	-0.52x	0.69x	-1.37x	7.50x	-18.09x	-3.23x	-50.50x	-4.34x	-5.25x
FCF Conversion	-0.24x	1.86x	503.32x	2.20x	1.24x	-0.08x	-1.08x	1.02x	0.84x	1.10x
Revenue Growth	32.47%	31.4%	37.93%	16.63%	87.2%	-35.04%	11.13%	-27.53%	34.1%	-10.48%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Research and Development Revenue	-	-	-	-	-	-	-	284.01M	479.06M	412.06M
Research and Development Revenue Growth	-	-	-	-	-	-	-	-	68.68%	-13.98%
Collaborative Agreement Revenue	-	-	-	-	-	-	-	207.22M	352.66M	332.65M
Collaborative Agreement Revenue Growth	-	-	-	-	-	-	-	-	70.18%	-5.67%
Commercial	-	-	-	254.92M	352.45M	364.7M	342.39M	303.36M	308.59M	293.08M
Commercial Growth	-	-	-	-	38.26%	3.48%	-6.12%	-11.40%	1.73%	-5.03%
SPINRAZA Royalties	-	-	-	237.93M	292.99M	-	-	-	240.38M	216.09M
SPINRAZA Royalties Growth	-	-	-	-	23.14%	-	-	-	-	-10.10%
Other Commercial	-	-	-	-	-	-	-	-	68.21M	56.78M
Other Commercial Growth	-	-	-	-	-	-	-	-	-	-16.76%
Product	-	-	-	2.24M	42.25M	70M	-	30.05M	34.91M	34.19M
Product Growth	-	-	-	-	1788.82%	65.67%	-	-	16.18%	-2.07%
Other	-	-	-	-	-	-	-	-	-	22.59M
Other Growth	-	-	-	-	-	-	-	-	-	-
Licensing and Other Royalties	-	-	-	14.76M	17.2M	8.12M	19.12M	30.99M	33.3M	-
Licensing and Other Royalties Growth	-	-	-	-	16.60%	-52.82%	135.54%	62.11%	7.44%	-
Spinraza Royalties	-	-	-	-	-	286.58M	267.78M	242.31M	-	-
Spinraza Royalties Growth	-	-	-	-	-	-	-6.56%	-9.51%	-	-
Eplontersen Joint Development Revenue	-	-	-	-	-	-	-	76.79M	-	-
Eplontersen Joint Development Revenue Growth	-	-	-	-	-	-	-	-	-	-
Research and Development Revenue Under Collaborative Agreements	-	-	-	344.75M	770.15M	364.56M	468.06M	-	-	-
Research and Development Revenue Under Collaborative Agreements Growth	-	-	-	-	123.39%	-52.66%	28.39%	-	-	-
TEGSEDI and WAYLIVRA	-	-	-	-	-	-	55.5M	-	-	-
TEGSEDI and WAYLIVRA Growth	-	-	-	-	-	-	-	-	-	-
Akcea Therapeutics	-	-	-	-	-	-	-	-	-	-
Akcea Therapeutics Growth	-	-	-	-	-	-	-	-	-	-
Nusinersen	40M	-	-	-	-	-	-	-	-	-
Nusinersen Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Ionis Pharmaceuticals, Inc. (IONS) reported $967.0M in revenue for fiscal year 2024. This represents a 876% increase from $99.1M in 2011.

Ionis Pharmaceuticals, Inc. (IONS) saw revenue decline by 10.5% over the past year.

Ionis Pharmaceuticals, Inc. (IONS) reported a net loss of $256.3M for fiscal year 2024.

Dividend & Returns

Ionis Pharmaceuticals, Inc. (IONS) has a return on equity (ROE) of -93.1%. Negative ROE indicates the company is unprofitable.

Ionis Pharmaceuticals, Inc. (IONS) had negative free cash flow of $302.7M in fiscal year 2024, likely due to heavy capital investments.